Denali Therapeutics, Inc. (DNLI)

23.26 -0.50 (-2.08%) USD  |  NASDAQ  |  Sep 01, 16:00
23.26 0.00 (0.00%) After-Hours: 20:00
More

Denali Therapeutics Research and Development Expense (Annual) : 418.78M for Dec. 31, 2025

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for DNLI.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Research and Development Expense (Annual) Data

View and export this data back to 2015. Start Trial.
Date Value
December 31, 2025 418.78M
December 31, 2024 396.44M
December 31, 2023 423.88M
December 31, 2022 358.73M
December 31, 2021 265.35M
December 31, 2020 212.62M
Date Value
December 31, 2019 191.88M
December 31, 2018 135.28M
December 31, 2017 71.38M
December 31, 2016 74.23M
December 31, 2015 11.45M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. 585.26M
Oncolytics Biotech, Inc. 13.31M
Sangamo Therapeutics, Inc. 112.67M
Sarepta Therapeutics, Inc. 1.493B
Anixa Biosciences, Inc. 5.071M